nodes	percent_of_prediction	percent_of_DWPC	metapath
Paliperidone—ADRA1B—vas deferens—urinary bladder cancer	0.0975	0.424	CbGeAlD
Paliperidone—HTR2A—urine—urinary bladder cancer	0.00881	0.0383	CbGeAlD
Paliperidone—CYP3A4—urine—urinary bladder cancer	0.00816	0.0355	CbGeAlD
Paliperidone—CYP2D6—urine—urinary bladder cancer	0.00803	0.0349	CbGeAlD
Paliperidone—ADRA1B—renal system—urinary bladder cancer	0.00594	0.0258	CbGeAlD
Paliperidone—ADRA1A—prostate gland—urinary bladder cancer	0.00489	0.0213	CbGeAlD
Paliperidone—ADRA2C—prostate gland—urinary bladder cancer	0.00466	0.0203	CbGeAlD
Paliperidone—ADRA2C—seminal vesicle—urinary bladder cancer	0.00394	0.0171	CbGeAlD
Paliperidone—CYP3A5—prostate gland—urinary bladder cancer	0.0039	0.017	CbGeAlD
Paliperidone—HRH1—prostate gland—urinary bladder cancer	0.00379	0.0165	CbGeAlD
Paliperidone—ADRA2A—prostate gland—urinary bladder cancer	0.00372	0.0162	CbGeAlD
Paliperidone—HTR1A—renal system—urinary bladder cancer	0.00362	0.0157	CbGeAlD
Paliperidone—ADRA1A—epithelium—urinary bladder cancer	0.00359	0.0156	CbGeAlD
Paliperidone—HTR1B—female reproductive system—urinary bladder cancer	0.00359	0.0156	CbGeAlD
Paliperidone—HTR1D—female reproductive system—urinary bladder cancer	0.00348	0.0151	CbGeAlD
Paliperidone—HTR2C—female reproductive system—urinary bladder cancer	0.00344	0.015	CbGeAlD
Paliperidone—ADRA1A—renal system—urinary bladder cancer	0.00333	0.0145	CbGeAlD
Paliperidone—ADRA2C—renal system—urinary bladder cancer	0.00318	0.0138	CbGeAlD
Paliperidone—ADRA2A—seminal vesicle—urinary bladder cancer	0.00315	0.0137	CbGeAlD
Paliperidone—ADRA2C—urethra—urinary bladder cancer	0.00312	0.0136	CbGeAlD
Paliperidone—HRH1—epithelium—urinary bladder cancer	0.00278	0.0121	CbGeAlD
Paliperidone—HRH1—smooth muscle tissue—urinary bladder cancer	0.00268	0.0117	CbGeAlD
Paliperidone—CYP3A5—renal system—urinary bladder cancer	0.00266	0.0116	CbGeAlD
Paliperidone—HRH1—urethra—urinary bladder cancer	0.00254	0.011	CbGeAlD
Paliperidone—ADRA2A—urethra—urinary bladder cancer	0.00249	0.0108	CbGeAlD
Paliperidone—HTR2A—epithelium—urinary bladder cancer	0.00232	0.0101	CbGeAlD
Paliperidone—ADRA2C—vagina—urinary bladder cancer	0.0023	0.01	CbGeAlD
Paliperidone—HTR2A—smooth muscle tissue—urinary bladder cancer	0.00224	0.00973	CbGeAlD
Paliperidone—HTR2A—renal system—urinary bladder cancer	0.00216	0.00937	CbGeAlD
Paliperidone—HRH1—female reproductive system—urinary bladder cancer	0.00207	0.00898	CbGeAlD
Paliperidone—ADRA2A—female reproductive system—urinary bladder cancer	0.00203	0.00883	CbGeAlD
Paliperidone—CYP3A4—renal system—urinary bladder cancer	0.002	0.00867	CbGeAlD
Paliperidone—CYP2D6—renal system—urinary bladder cancer	0.00196	0.00854	CbGeAlD
Paliperidone—CYP3A5—vagina—urinary bladder cancer	0.00193	0.00837	CbGeAlD
Paliperidone—HRH1—vagina—urinary bladder cancer	0.00187	0.00813	CbGeAlD
Paliperidone—ADRA2A—vagina—urinary bladder cancer	0.00184	0.00798	CbGeAlD
Paliperidone—HTR2A—female reproductive system—urinary bladder cancer	0.00173	0.0075	CbGeAlD
Paliperidone—CYP3A4—female reproductive system—urinary bladder cancer	0.0016	0.00695	CbGeAlD
Paliperidone—CYP2D6—female reproductive system—urinary bladder cancer	0.00157	0.00684	CbGeAlD
Paliperidone—HTR2A—vagina—urinary bladder cancer	0.00156	0.00679	CbGeAlD
Paliperidone—ADRA2C—lymph node—urinary bladder cancer	0.00149	0.00647	CbGeAlD
Paliperidone—HRH1—lymph node—urinary bladder cancer	0.00121	0.00526	CbGeAlD
Paliperidone—ADRA2A—lymph node—urinary bladder cancer	0.00119	0.00516	CbGeAlD
Paliperidone—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.00042	0.000573	CcSEcCtD
Paliperidone—Asthenia—Cisplatin—urinary bladder cancer	0.000419	0.000572	CcSEcCtD
Paliperidone—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000418	0.000571	CcSEcCtD
Paliperidone—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000417	0.000569	CcSEcCtD
Paliperidone—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000416	0.000567	CcSEcCtD
Paliperidone—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000415	0.000566	CcSEcCtD
Paliperidone—Urethral disorder—Epirubicin—urinary bladder cancer	0.000414	0.000565	CcSEcCtD
Paliperidone—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000411	0.000561	CcSEcCtD
Paliperidone—Epistaxis—Doxorubicin—urinary bladder cancer	0.00041	0.00056	CcSEcCtD
Paliperidone—Angiopathy—Methotrexate—urinary bladder cancer	0.000409	0.000558	CcSEcCtD
Paliperidone—Sinusitis—Doxorubicin—urinary bladder cancer	0.000408	0.000557	CcSEcCtD
Paliperidone—Immune system disorder—Methotrexate—urinary bladder cancer	0.000407	0.000556	CcSEcCtD
Paliperidone—Dizziness—Fluorouracil—urinary bladder cancer	0.000407	0.000556	CcSEcCtD
Paliperidone—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000406	0.000555	CcSEcCtD
Paliperidone—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000406	0.000554	CcSEcCtD
Paliperidone—Chills—Methotrexate—urinary bladder cancer	0.000404	0.000552	CcSEcCtD
Paliperidone—Diarrhoea—Cisplatin—urinary bladder cancer	0.000399	0.000545	CcSEcCtD
Paliperidone—Alopecia—Methotrexate—urinary bladder cancer	0.000398	0.000544	CcSEcCtD
Paliperidone—Vomiting—Gemcitabine—urinary bladder cancer	0.000398	0.000544	CcSEcCtD
Paliperidone—Bradycardia—Doxorubicin—urinary bladder cancer	0.000397	0.000543	CcSEcCtD
Paliperidone—Mental disorder—Methotrexate—urinary bladder cancer	0.000395	0.000539	CcSEcCtD
Paliperidone—Rash—Gemcitabine—urinary bladder cancer	0.000395	0.000539	CcSEcCtD
Paliperidone—Dermatitis—Gemcitabine—urinary bladder cancer	0.000394	0.000539	CcSEcCtD
Paliperidone—Eye disorder—Epirubicin—urinary bladder cancer	0.000394	0.000538	CcSEcCtD
Paliperidone—Hypersensitivity—Etoposide—urinary bladder cancer	0.000394	0.000538	CcSEcCtD
Paliperidone—Tinnitus—Epirubicin—urinary bladder cancer	0.000393	0.000537	CcSEcCtD
Paliperidone—Erythema—Methotrexate—urinary bladder cancer	0.000392	0.000536	CcSEcCtD
Paliperidone—Malnutrition—Methotrexate—urinary bladder cancer	0.000392	0.000536	CcSEcCtD
Paliperidone—Headache—Gemcitabine—urinary bladder cancer	0.000392	0.000536	CcSEcCtD
Paliperidone—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000391	0.000535	CcSEcCtD
Paliperidone—Flushing—Epirubicin—urinary bladder cancer	0.000391	0.000535	CcSEcCtD
Paliperidone—Vomiting—Fluorouracil—urinary bladder cancer	0.000391	0.000534	CcSEcCtD
Paliperidone—Rhinitis—Doxorubicin—urinary bladder cancer	0.000391	0.000534	CcSEcCtD
Paliperidone—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000388	0.00053	CcSEcCtD
Paliperidone—Rash—Fluorouracil—urinary bladder cancer	0.000388	0.00053	CcSEcCtD
Paliperidone—Dermatitis—Fluorouracil—urinary bladder cancer	0.000388	0.000529	CcSEcCtD
Paliperidone—Headache—Fluorouracil—urinary bladder cancer	0.000386	0.000527	CcSEcCtD
Paliperidone—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000385	0.000526	CcSEcCtD
Paliperidone—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000384	0.000525	CcSEcCtD
Paliperidone—Dysgeusia—Methotrexate—urinary bladder cancer	0.000384	0.000525	CcSEcCtD
Paliperidone—Asthenia—Etoposide—urinary bladder cancer	0.000384	0.000524	CcSEcCtD
Paliperidone—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000384	0.000524	CcSEcCtD
Paliperidone—Angiopathy—Epirubicin—urinary bladder cancer	0.000383	0.000523	CcSEcCtD
Paliperidone—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000383	0.000522	CcSEcCtD
Paliperidone—Immune system disorder—Epirubicin—urinary bladder cancer	0.000381	0.00052	CcSEcCtD
Paliperidone—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.00038	0.000519	CcSEcCtD
Paliperidone—Back pain—Methotrexate—urinary bladder cancer	0.00038	0.000518	CcSEcCtD
Paliperidone—Chills—Epirubicin—urinary bladder cancer	0.000378	0.000517	CcSEcCtD
Paliperidone—Pruritus—Etoposide—urinary bladder cancer	0.000378	0.000516	CcSEcCtD
Paliperidone—Alopecia—Epirubicin—urinary bladder cancer	0.000373	0.000509	CcSEcCtD
Paliperidone—Nausea—Gemcitabine—urinary bladder cancer	0.000372	0.000508	CcSEcCtD
Paliperidone—Vomiting—Cisplatin—urinary bladder cancer	0.000371	0.000507	CcSEcCtD
Paliperidone—Vision blurred—Methotrexate—urinary bladder cancer	0.00037	0.000505	CcSEcCtD
Paliperidone—Mental disorder—Epirubicin—urinary bladder cancer	0.00037	0.000505	CcSEcCtD
Paliperidone—Rash—Cisplatin—urinary bladder cancer	0.000368	0.000502	CcSEcCtD
Paliperidone—Dermatitis—Cisplatin—urinary bladder cancer	0.000368	0.000502	CcSEcCtD
Paliperidone—Malnutrition—Epirubicin—urinary bladder cancer	0.000367	0.000501	CcSEcCtD
Paliperidone—Erythema—Epirubicin—urinary bladder cancer	0.000367	0.000501	CcSEcCtD
Paliperidone—Diarrhoea—Etoposide—urinary bladder cancer	0.000366	0.000499	CcSEcCtD
Paliperidone—Nausea—Fluorouracil—urinary bladder cancer	0.000366	0.000499	CcSEcCtD
Paliperidone—Eye disorder—Doxorubicin—urinary bladder cancer	0.000365	0.000498	CcSEcCtD
Paliperidone—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000364	0.000497	CcSEcCtD
Paliperidone—Tinnitus—Doxorubicin—urinary bladder cancer	0.000364	0.000497	CcSEcCtD
Paliperidone—Anaemia—Methotrexate—urinary bladder cancer	0.000363	0.000495	CcSEcCtD
Paliperidone—Flushing—Doxorubicin—urinary bladder cancer	0.000362	0.000495	CcSEcCtD
Paliperidone—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000362	0.000495	CcSEcCtD
Paliperidone—Flatulence—Epirubicin—urinary bladder cancer	0.000362	0.000494	CcSEcCtD
Paliperidone—Tension—Epirubicin—urinary bladder cancer	0.00036	0.000492	CcSEcCtD
Paliperidone—Dysgeusia—Epirubicin—urinary bladder cancer	0.00036	0.000491	CcSEcCtD
Paliperidone—Nervousness—Epirubicin—urinary bladder cancer	0.000357	0.000487	CcSEcCtD
Paliperidone—Back pain—Epirubicin—urinary bladder cancer	0.000355	0.000485	CcSEcCtD
Paliperidone—Angiopathy—Doxorubicin—urinary bladder cancer	0.000354	0.000484	CcSEcCtD
Paliperidone—Malaise—Methotrexate—urinary bladder cancer	0.000354	0.000483	CcSEcCtD
Paliperidone—Dizziness—Etoposide—urinary bladder cancer	0.000354	0.000483	CcSEcCtD
Paliperidone—Muscle spasms—Epirubicin—urinary bladder cancer	0.000353	0.000482	CcSEcCtD
Paliperidone—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000353	0.000481	CcSEcCtD
Paliperidone—Vertigo—Methotrexate—urinary bladder cancer	0.000353	0.000481	CcSEcCtD
Paliperidone—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000352	0.00048	CcSEcCtD
Paliperidone—Leukopenia—Methotrexate—urinary bladder cancer	0.000351	0.00048	CcSEcCtD
Paliperidone—Chills—Doxorubicin—urinary bladder cancer	0.00035	0.000478	CcSEcCtD
Paliperidone—Nausea—Cisplatin—urinary bladder cancer	0.000347	0.000473	CcSEcCtD
Paliperidone—Vision blurred—Epirubicin—urinary bladder cancer	0.000346	0.000473	CcSEcCtD
Paliperidone—Alopecia—Doxorubicin—urinary bladder cancer	0.000345	0.000471	CcSEcCtD
Paliperidone—Cough—Methotrexate—urinary bladder cancer	0.000342	0.000468	CcSEcCtD
Paliperidone—Mental disorder—Doxorubicin—urinary bladder cancer	0.000342	0.000467	CcSEcCtD
Paliperidone—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000341	0.000465	CcSEcCtD
Paliperidone—Convulsion—Methotrexate—urinary bladder cancer	0.00034	0.000464	CcSEcCtD
Paliperidone—Vomiting—Etoposide—urinary bladder cancer	0.00034	0.000464	CcSEcCtD
Paliperidone—Erythema—Doxorubicin—urinary bladder cancer	0.00034	0.000464	CcSEcCtD
Paliperidone—Malnutrition—Doxorubicin—urinary bladder cancer	0.00034	0.000464	CcSEcCtD
Paliperidone—Anaemia—Epirubicin—urinary bladder cancer	0.000339	0.000463	CcSEcCtD
Paliperidone—Agitation—Epirubicin—urinary bladder cancer	0.000337	0.000461	CcSEcCtD
Paliperidone—Rash—Etoposide—urinary bladder cancer	0.000337	0.00046	CcSEcCtD
Paliperidone—Dermatitis—Etoposide—urinary bladder cancer	0.000337	0.00046	CcSEcCtD
Paliperidone—Headache—Etoposide—urinary bladder cancer	0.000335	0.000457	CcSEcCtD
Paliperidone—Flatulence—Doxorubicin—urinary bladder cancer	0.000335	0.000457	CcSEcCtD
Paliperidone—Arthralgia—Methotrexate—urinary bladder cancer	0.000334	0.000456	CcSEcCtD
Paliperidone—Myalgia—Methotrexate—urinary bladder cancer	0.000334	0.000456	CcSEcCtD
Paliperidone—Chest pain—Methotrexate—urinary bladder cancer	0.000334	0.000456	CcSEcCtD
Paliperidone—Tension—Doxorubicin—urinary bladder cancer	0.000333	0.000455	CcSEcCtD
Paliperidone—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000333	0.000454	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000332	0.000453	CcSEcCtD
Paliperidone—Malaise—Epirubicin—urinary bladder cancer	0.000331	0.000452	CcSEcCtD
Paliperidone—Discomfort—Methotrexate—urinary bladder cancer	0.00033	0.000451	CcSEcCtD
Paliperidone—Nervousness—Doxorubicin—urinary bladder cancer	0.00033	0.000451	CcSEcCtD
Paliperidone—Vertigo—Epirubicin—urinary bladder cancer	0.00033	0.00045	CcSEcCtD
Paliperidone—Syncope—Epirubicin—urinary bladder cancer	0.000329	0.00045	CcSEcCtD
Paliperidone—Leukopenia—Epirubicin—urinary bladder cancer	0.000329	0.000449	CcSEcCtD
Paliperidone—Back pain—Doxorubicin—urinary bladder cancer	0.000329	0.000449	CcSEcCtD
Paliperidone—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000327	0.000446	CcSEcCtD
Paliperidone—Palpitations—Epirubicin—urinary bladder cancer	0.000325	0.000443	CcSEcCtD
Paliperidone—Confusional state—Methotrexate—urinary bladder cancer	0.000323	0.000441	CcSEcCtD
Paliperidone—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000323	0.000441	CcSEcCtD
Paliperidone—Cough—Epirubicin—urinary bladder cancer	0.00032	0.000438	CcSEcCtD
Paliperidone—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.00032	0.000437	CcSEcCtD
Paliperidone—Vision blurred—Doxorubicin—urinary bladder cancer	0.00032	0.000437	CcSEcCtD
Paliperidone—Convulsion—Epirubicin—urinary bladder cancer	0.000318	0.000434	CcSEcCtD
Paliperidone—Infection—Methotrexate—urinary bladder cancer	0.000318	0.000434	CcSEcCtD
Paliperidone—Nausea—Etoposide—urinary bladder cancer	0.000318	0.000434	CcSEcCtD
Paliperidone—Hypertension—Epirubicin—urinary bladder cancer	0.000317	0.000433	CcSEcCtD
Paliperidone—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000315	0.00043	CcSEcCtD
Paliperidone—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000314	0.000429	CcSEcCtD
Paliperidone—Anaemia—Doxorubicin—urinary bladder cancer	0.000314	0.000429	CcSEcCtD
Paliperidone—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000314	0.000428	CcSEcCtD
Paliperidone—Arthralgia—Epirubicin—urinary bladder cancer	0.000313	0.000427	CcSEcCtD
Paliperidone—Chest pain—Epirubicin—urinary bladder cancer	0.000313	0.000427	CcSEcCtD
Paliperidone—Myalgia—Epirubicin—urinary bladder cancer	0.000313	0.000427	CcSEcCtD
Paliperidone—Agitation—Doxorubicin—urinary bladder cancer	0.000312	0.000426	CcSEcCtD
Paliperidone—Anxiety—Epirubicin—urinary bladder cancer	0.000312	0.000425	CcSEcCtD
Paliperidone—Skin disorder—Methotrexate—urinary bladder cancer	0.000311	0.000425	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.00031	0.000424	CcSEcCtD
Paliperidone—Discomfort—Epirubicin—urinary bladder cancer	0.000309	0.000422	CcSEcCtD
Paliperidone—Malaise—Doxorubicin—urinary bladder cancer	0.000306	0.000418	CcSEcCtD
Paliperidone—Dry mouth—Epirubicin—urinary bladder cancer	0.000306	0.000417	CcSEcCtD
Paliperidone—Vertigo—Doxorubicin—urinary bladder cancer	0.000305	0.000417	CcSEcCtD
Paliperidone—Anorexia—Methotrexate—urinary bladder cancer	0.000305	0.000417	CcSEcCtD
Paliperidone—Syncope—Doxorubicin—urinary bladder cancer	0.000305	0.000416	CcSEcCtD
Paliperidone—Leukopenia—Doxorubicin—urinary bladder cancer	0.000304	0.000415	CcSEcCtD
Paliperidone—Confusional state—Epirubicin—urinary bladder cancer	0.000302	0.000413	CcSEcCtD
Paliperidone—Palpitations—Doxorubicin—urinary bladder cancer	0.0003	0.00041	CcSEcCtD
Paliperidone—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.0003	0.000409	CcSEcCtD
Paliperidone—Oedema—Epirubicin—urinary bladder cancer	0.0003	0.000409	CcSEcCtD
Paliperidone—Hypotension—Methotrexate—urinary bladder cancer	0.000299	0.000409	CcSEcCtD
Paliperidone—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000299	0.000408	CcSEcCtD
Paliperidone—Infection—Epirubicin—urinary bladder cancer	0.000298	0.000407	CcSEcCtD
Paliperidone—Cough—Doxorubicin—urinary bladder cancer	0.000296	0.000405	CcSEcCtD
Paliperidone—Shock—Epirubicin—urinary bladder cancer	0.000295	0.000403	CcSEcCtD
Paliperidone—Convulsion—Doxorubicin—urinary bladder cancer	0.000294	0.000402	CcSEcCtD
Paliperidone—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000294	0.000401	CcSEcCtD
Paliperidone—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000293	0.000401	CcSEcCtD
Paliperidone—Hypertension—Doxorubicin—urinary bladder cancer	0.000293	0.000401	CcSEcCtD
Paliperidone—Tachycardia—Epirubicin—urinary bladder cancer	0.000292	0.000399	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000292	0.000398	CcSEcCtD
Paliperidone—Skin disorder—Epirubicin—urinary bladder cancer	0.000291	0.000397	CcSEcCtD
Paliperidone—Insomnia—Methotrexate—urinary bladder cancer	0.00029	0.000395	CcSEcCtD
Paliperidone—Arthralgia—Doxorubicin—urinary bladder cancer	0.000289	0.000395	CcSEcCtD
Paliperidone—Myalgia—Doxorubicin—urinary bladder cancer	0.000289	0.000395	CcSEcCtD
Paliperidone—Chest pain—Doxorubicin—urinary bladder cancer	0.000289	0.000395	CcSEcCtD
Paliperidone—Anxiety—Doxorubicin—urinary bladder cancer	0.000288	0.000394	CcSEcCtD
Paliperidone—Paraesthesia—Methotrexate—urinary bladder cancer	0.000288	0.000393	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000287	0.000392	CcSEcCtD
Paliperidone—Discomfort—Doxorubicin—urinary bladder cancer	0.000286	0.00039	CcSEcCtD
Paliperidone—Anorexia—Epirubicin—urinary bladder cancer	0.000286	0.00039	CcSEcCtD
Paliperidone—Dyspnoea—Methotrexate—urinary bladder cancer	0.000286	0.00039	CcSEcCtD
Paliperidone—Somnolence—Methotrexate—urinary bladder cancer	0.000285	0.000389	CcSEcCtD
Paliperidone—Dry mouth—Doxorubicin—urinary bladder cancer	0.000283	0.000386	CcSEcCtD
Paliperidone—Dyspepsia—Methotrexate—urinary bladder cancer	0.000282	0.000385	CcSEcCtD
Paliperidone—Hypotension—Epirubicin—urinary bladder cancer	0.00028	0.000382	CcSEcCtD
Paliperidone—Confusional state—Doxorubicin—urinary bladder cancer	0.00028	0.000382	CcSEcCtD
Paliperidone—Decreased appetite—Methotrexate—urinary bladder cancer	0.000278	0.00038	CcSEcCtD
Paliperidone—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000277	0.000379	CcSEcCtD
Paliperidone—Oedema—Doxorubicin—urinary bladder cancer	0.000277	0.000379	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000276	0.000377	CcSEcCtD
Paliperidone—Fatigue—Methotrexate—urinary bladder cancer	0.000276	0.000377	CcSEcCtD
Paliperidone—Infection—Doxorubicin—urinary bladder cancer	0.000275	0.000376	CcSEcCtD
Paliperidone—Pain—Methotrexate—urinary bladder cancer	0.000274	0.000374	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000273	0.000373	CcSEcCtD
Paliperidone—Shock—Doxorubicin—urinary bladder cancer	0.000273	0.000372	CcSEcCtD
Paliperidone—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000272	0.000371	CcSEcCtD
Paliperidone—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000272	0.000371	CcSEcCtD
Paliperidone—Insomnia—Epirubicin—urinary bladder cancer	0.000271	0.00037	CcSEcCtD
Paliperidone—Tachycardia—Doxorubicin—urinary bladder cancer	0.000271	0.00037	CcSEcCtD
Paliperidone—Skin disorder—Doxorubicin—urinary bladder cancer	0.000269	0.000368	CcSEcCtD
Paliperidone—Paraesthesia—Epirubicin—urinary bladder cancer	0.000269	0.000367	CcSEcCtD
Paliperidone—Dyspnoea—Epirubicin—urinary bladder cancer	0.000267	0.000365	CcSEcCtD
Paliperidone—Somnolence—Epirubicin—urinary bladder cancer	0.000266	0.000364	CcSEcCtD
Paliperidone—Anorexia—Doxorubicin—urinary bladder cancer	0.000264	0.000361	CcSEcCtD
Paliperidone—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000264	0.00036	CcSEcCtD
Paliperidone—Dyspepsia—Epirubicin—urinary bladder cancer	0.000264	0.00036	CcSEcCtD
Paliperidone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000262	0.000358	CcSEcCtD
Paliperidone—Decreased appetite—Epirubicin—urinary bladder cancer	0.000261	0.000356	CcSEcCtD
Paliperidone—Hypotension—Doxorubicin—urinary bladder cancer	0.000259	0.000354	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000259	0.000353	CcSEcCtD
Paliperidone—Fatigue—Epirubicin—urinary bladder cancer	0.000258	0.000353	CcSEcCtD
Paliperidone—Pain—Epirubicin—urinary bladder cancer	0.000256	0.00035	CcSEcCtD
Paliperidone—Constipation—Epirubicin—urinary bladder cancer	0.000256	0.00035	CcSEcCtD
Paliperidone—Urticaria—Methotrexate—urinary bladder cancer	0.000254	0.000347	CcSEcCtD
Paliperidone—Abdominal pain—Methotrexate—urinary bladder cancer	0.000253	0.000346	CcSEcCtD
Paliperidone—Body temperature increased—Methotrexate—urinary bladder cancer	0.000253	0.000346	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000253	0.000345	CcSEcCtD
Paliperidone—Insomnia—Doxorubicin—urinary bladder cancer	0.000251	0.000342	CcSEcCtD
Paliperidone—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000249	0.00034	CcSEcCtD
Paliperidone—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000247	0.000338	CcSEcCtD
Paliperidone—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000247	0.000337	CcSEcCtD
Paliperidone—Somnolence—Doxorubicin—urinary bladder cancer	0.000247	0.000337	CcSEcCtD
Paliperidone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000245	0.000335	CcSEcCtD
Paliperidone—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000244	0.000333	CcSEcCtD
Paliperidone—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000241	0.000329	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000239	0.000327	CcSEcCtD
Paliperidone—Fatigue—Doxorubicin—urinary bladder cancer	0.000239	0.000326	CcSEcCtD
Paliperidone—Urticaria—Epirubicin—urinary bladder cancer	0.000238	0.000325	CcSEcCtD
Paliperidone—Pain—Doxorubicin—urinary bladder cancer	0.000237	0.000324	CcSEcCtD
Paliperidone—Constipation—Doxorubicin—urinary bladder cancer	0.000237	0.000324	CcSEcCtD
Paliperidone—Body temperature increased—Epirubicin—urinary bladder cancer	0.000237	0.000323	CcSEcCtD
Paliperidone—Abdominal pain—Epirubicin—urinary bladder cancer	0.000237	0.000323	CcSEcCtD
Paliperidone—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000236	0.000322	CcSEcCtD
Paliperidone—Asthenia—Methotrexate—urinary bladder cancer	0.00023	0.000314	CcSEcCtD
Paliperidone—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000229	0.000312	CcSEcCtD
Paliperidone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000227	0.00031	CcSEcCtD
Paliperidone—Pruritus—Methotrexate—urinary bladder cancer	0.000227	0.000309	CcSEcCtD
Paliperidone—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000221	0.000301	CcSEcCtD
Paliperidone—Urticaria—Doxorubicin—urinary bladder cancer	0.00022	0.000301	CcSEcCtD
Paliperidone—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000219	0.000299	CcSEcCtD
Paliperidone—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000219	0.000299	CcSEcCtD
Paliperidone—Diarrhoea—Methotrexate—urinary bladder cancer	0.000219	0.000299	CcSEcCtD
Paliperidone—Asthenia—Epirubicin—urinary bladder cancer	0.000215	0.000294	CcSEcCtD
Paliperidone—Pruritus—Epirubicin—urinary bladder cancer	0.000212	0.000289	CcSEcCtD
Paliperidone—Dizziness—Methotrexate—urinary bladder cancer	0.000212	0.000289	CcSEcCtD
Paliperidone—Diarrhoea—Epirubicin—urinary bladder cancer	0.000205	0.00028	CcSEcCtD
Paliperidone—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000204	0.000279	CcSEcCtD
Paliperidone—Vomiting—Methotrexate—urinary bladder cancer	0.000204	0.000278	CcSEcCtD
Paliperidone—Rash—Methotrexate—urinary bladder cancer	0.000202	0.000276	CcSEcCtD
Paliperidone—Dermatitis—Methotrexate—urinary bladder cancer	0.000202	0.000275	CcSEcCtD
Paliperidone—Headache—Methotrexate—urinary bladder cancer	0.000201	0.000274	CcSEcCtD
Paliperidone—Asthenia—Doxorubicin—urinary bladder cancer	0.000199	0.000272	CcSEcCtD
Paliperidone—Dizziness—Epirubicin—urinary bladder cancer	0.000198	0.000271	CcSEcCtD
Paliperidone—Pruritus—Doxorubicin—urinary bladder cancer	0.000196	0.000268	CcSEcCtD
Paliperidone—Vomiting—Epirubicin—urinary bladder cancer	0.000191	0.00026	CcSEcCtD
Paliperidone—Nausea—Methotrexate—urinary bladder cancer	0.00019	0.00026	CcSEcCtD
Paliperidone—Diarrhoea—Doxorubicin—urinary bladder cancer	0.00019	0.000259	CcSEcCtD
Paliperidone—Rash—Epirubicin—urinary bladder cancer	0.000189	0.000258	CcSEcCtD
Paliperidone—Dermatitis—Epirubicin—urinary bladder cancer	0.000189	0.000258	CcSEcCtD
Paliperidone—Headache—Epirubicin—urinary bladder cancer	0.000188	0.000256	CcSEcCtD
Paliperidone—Dizziness—Doxorubicin—urinary bladder cancer	0.000183	0.00025	CcSEcCtD
Paliperidone—Nausea—Epirubicin—urinary bladder cancer	0.000178	0.000243	CcSEcCtD
Paliperidone—Vomiting—Doxorubicin—urinary bladder cancer	0.000176	0.000241	CcSEcCtD
Paliperidone—Rash—Doxorubicin—urinary bladder cancer	0.000175	0.000239	CcSEcCtD
Paliperidone—Dermatitis—Doxorubicin—urinary bladder cancer	0.000175	0.000239	CcSEcCtD
Paliperidone—Headache—Doxorubicin—urinary bladder cancer	0.000174	0.000237	CcSEcCtD
Paliperidone—Nausea—Doxorubicin—urinary bladder cancer	0.000165	0.000225	CcSEcCtD
Paliperidone—ADRA1B—Signaling by GPCR—KRAS—urinary bladder cancer	7.64e-06	0.000204	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—IL2—urinary bladder cancer	7.63e-06	0.000203	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—EP300—urinary bladder cancer	7.6e-06	0.000203	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CREBBP—urinary bladder cancer	7.59e-06	0.000202	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—RHOA—urinary bladder cancer	7.56e-06	0.000202	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—IL2—urinary bladder cancer	7.52e-06	0.000201	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—SRC—urinary bladder cancer	7.51e-06	0.0002	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—ERBB2—urinary bladder cancer	7.5e-06	0.0002	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—IGF1—urinary bladder cancer	7.49e-06	0.0002	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CREBBP—urinary bladder cancer	7.46e-06	0.000199	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—EGFR—urinary bladder cancer	7.45e-06	0.000199	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CREBBP—urinary bladder cancer	7.45e-06	0.000199	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—RHOA—urinary bladder cancer	7.44e-06	0.000198	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	7.44e-06	0.000198	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—CCND1—urinary bladder cancer	7.43e-06	0.000198	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—SRC—urinary bladder cancer	7.39e-06	0.000197	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—IGF1—urinary bladder cancer	7.37e-06	0.000196	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—GPX1—urinary bladder cancer	7.36e-06	0.000196	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—IGF1—urinary bladder cancer	7.35e-06	0.000196	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—CCND1—urinary bladder cancer	7.33e-06	0.000196	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—EGFR—urinary bladder cancer	7.33e-06	0.000196	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—EGFR—urinary bladder cancer	7.32e-06	0.000195	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CREBBP—urinary bladder cancer	7.31e-06	0.000195	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—ERBB2—urinary bladder cancer	7.24e-06	0.000193	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	7.23e-06	0.000193	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IGF1—urinary bladder cancer	7.22e-06	0.000192	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—MMP9—urinary bladder cancer	7.22e-06	0.000192	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—ERBB2—urinary bladder cancer	7.2e-06	0.000192	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—CDKN1A—urinary bladder cancer	7.19e-06	0.000192	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—EGFR—urinary bladder cancer	7.18e-06	0.000191	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—PTEN—urinary bladder cancer	7.17e-06	0.000191	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—PTEN—urinary bladder cancer	7.14e-06	0.00019	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—MMP9—urinary bladder cancer	7.12e-06	0.00019	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—CXCL8—urinary bladder cancer	7.11e-06	0.000189	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—CDKN1A—urinary bladder cancer	7.1e-06	0.000189	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—PTEN—urinary bladder cancer	7.08e-06	0.000189	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—HRAS—urinary bladder cancer	7.06e-06	0.000188	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—KRAS—urinary bladder cancer	7.04e-06	0.000188	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—ERBB2—urinary bladder cancer	7e-06	0.000187	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—KRAS—urinary bladder cancer	6.93e-06	0.000185	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—KRAS—urinary bladder cancer	6.91e-06	0.000184	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—ERBB2—urinary bladder cancer	6.89e-06	0.000184	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—MYC—urinary bladder cancer	6.87e-06	0.000183	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—RHOA—urinary bladder cancer	6.86e-06	0.000183	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—CXCL8—urinary bladder cancer	6.86e-06	0.000183	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—EP300—urinary bladder cancer	6.84e-06	0.000182	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—CXCL8—urinary bladder cancer	6.83e-06	0.000182	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—HRAS—urinary bladder cancer	6.82e-06	0.000182	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—EP300—urinary bladder cancer	6.81e-06	0.000182	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	6.79e-06	0.000181	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—IL2—urinary bladder cancer	6.79e-06	0.000181	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CREBBP—urinary bladder cancer	6.79e-06	0.000181	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—KRAS—urinary bladder cancer	6.78e-06	0.000181	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—HRAS—urinary bladder cancer	6.78e-06	0.000181	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—RHOA—urinary bladder cancer	6.75e-06	0.00018	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—EP300—urinary bladder cancer	6.75e-06	0.00018	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—RHOA—urinary bladder cancer	6.74e-06	0.00018	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—MYC—urinary bladder cancer	6.73e-06	0.000179	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—EGFR—urinary bladder cancer	6.72e-06	0.000179	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IGF1—urinary bladder cancer	6.71e-06	0.000179	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—EGFR—urinary bladder cancer	6.67e-06	0.000178	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—SRC—urinary bladder cancer	6.65e-06	0.000177	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PTGS2—urinary bladder cancer	6.65e-06	0.000177	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—CXCL8—urinary bladder cancer	6.64e-06	0.000177	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—MYC—urinary bladder cancer	6.62e-06	0.000177	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—CCND1—urinary bladder cancer	6.62e-06	0.000177	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—RHOA—urinary bladder cancer	6.61e-06	0.000176	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—HRAS—urinary bladder cancer	6.6e-06	0.000176	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—EGFR—urinary bladder cancer	6.58e-06	0.000176	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—SRC—urinary bladder cancer	6.57e-06	0.000175	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—IL2—urinary bladder cancer	6.56e-06	0.000175	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—NQO1—urinary bladder cancer	6.56e-06	0.000175	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—CXCL8—urinary bladder cancer	6.53e-06	0.000174	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	6.52e-06	0.000174	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—HRAS—urinary bladder cancer	6.49e-06	0.000173	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—EGFR—urinary bladder cancer	6.48e-06	0.000173	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MMP9—urinary bladder cancer	6.43e-06	0.000171	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—CDKN1A—urinary bladder cancer	6.41e-06	0.000171	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—CCND1—urinary bladder cancer	6.39e-06	0.00017	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—PTEN—urinary bladder cancer	6.39e-06	0.00017	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	6.36e-06	0.00017	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	6.35e-06	0.000169	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—KRAS—urinary bladder cancer	6.35e-06	0.000169	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—IL2—urinary bladder cancer	6.35e-06	0.000169	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	6.3e-06	0.000168	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	6.25e-06	0.000167	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—IL2—urinary bladder cancer	6.24e-06	0.000166	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	6.24e-06	0.000166	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—KRAS—urinary bladder cancer	6.22e-06	0.000166	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MMP9—urinary bladder cancer	6.21e-06	0.000165	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—CCND1—urinary bladder cancer	6.19e-06	0.000165	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	6.18e-06	0.000165	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	6.17e-06	0.000165	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—PTEN—urinary bladder cancer	6.17e-06	0.000164	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	6.15e-06	0.000164	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	6.14e-06	0.000164	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	6.14e-06	0.000164	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—ERBB2—urinary bladder cancer	6.12e-06	0.000163	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—KRAS—urinary bladder cancer	6.12e-06	0.000163	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—EP300—urinary bladder cancer	6.1e-06	0.000162	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	6.09e-06	0.000162	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—CCND1—urinary bladder cancer	6.09e-06	0.000162	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	6.02e-06	0.000161	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MMP9—urinary bladder cancer	6.01e-06	0.00016	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	5.99e-06	0.00016	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—CDKN1A—urinary bladder cancer	5.98e-06	0.00016	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—PTEN—urinary bladder cancer	5.97e-06	0.000159	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—MYC—urinary bladder cancer	5.96e-06	0.000159	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	5.93e-06	0.000158	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—SRC—urinary bladder cancer	5.93e-06	0.000158	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	5.91e-06	0.000158	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MMP9—urinary bladder cancer	5.91e-06	0.000158	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	5.89e-06	0.000157	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—CDKN1A—urinary bladder cancer	5.89e-06	0.000157	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—EP300—urinary bladder cancer	5.88e-06	0.000157	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—MYC—urinary bladder cancer	5.88e-06	0.000157	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	5.88e-06	0.000157	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—PTEN—urinary bladder cancer	5.88e-06	0.000157	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	5.85e-06	0.000156	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—EGFR—urinary bladder cancer	5.83e-06	0.000155	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CXCL8—urinary bladder cancer	5.8e-06	0.000155	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PTEN—urinary bladder cancer	5.8e-06	0.000155	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—HRAS—urinary bladder cancer	5.77e-06	0.000154	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—IL2—urinary bladder cancer	5.76e-06	0.000153	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—EGFR—urinary bladder cancer	5.75e-06	0.000153	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—SRC—urinary bladder cancer	5.72e-06	0.000153	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—EP300—urinary bladder cancer	5.69e-06	0.000152	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	5.69e-06	0.000152	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	5.69e-06	0.000152	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	5.66e-06	0.000151	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—IL2—urinary bladder cancer	5.65e-06	0.000151	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—TP53—urinary bladder cancer	5.65e-06	0.00015	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	5.61e-06	0.00015	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—EP300—urinary bladder cancer	5.6e-06	0.000149	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IL2—urinary bladder cancer	5.55e-06	0.000148	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—SRC—urinary bladder cancer	5.54e-06	0.000148	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—EP300—urinary bladder cancer	5.53e-06	0.000147	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—TP53—urinary bladder cancer	5.53e-06	0.000147	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	5.52e-06	0.000147	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	5.51e-06	0.000147	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—KRAS—urinary bladder cancer	5.51e-06	0.000147	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PPARG—urinary bladder cancer	5.51e-06	0.000147	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	5.47e-06	0.000146	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—SRC—urinary bladder cancer	5.45e-06	0.000145	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	5.45e-06	0.000145	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—TP53—urinary bladder cancer	5.44e-06	0.000145	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—KRAS—urinary bladder cancer	5.44e-06	0.000145	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	5.43e-06	0.000145	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	5.42e-06	0.000144	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CCND1—urinary bladder cancer	5.41e-06	0.000144	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—HRAS—urinary bladder cancer	5.4e-06	0.000144	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	5.39e-06	0.000144	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	5.36e-06	0.000143	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	5.36e-06	0.000143	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	5.35e-06	0.000143	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	5.34e-06	0.000142	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	5.33e-06	0.000142	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	5.33e-06	0.000142	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	5.32e-06	0.000142	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PTEN—urinary bladder cancer	5.31e-06	0.000142	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MYC—urinary bladder cancer	5.31e-06	0.000142	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	5.29e-06	0.000141	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—HRAS—urinary bladder cancer	5.29e-06	0.000141	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MMP9—urinary bladder cancer	5.25e-06	0.00014	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CDKN1A—urinary bladder cancer	5.23e-06	0.000139	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—PTEN—urinary bladder cancer	5.22e-06	0.000139	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—HRAS—urinary bladder cancer	5.2e-06	0.000139	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—EGFR—urinary bladder cancer	5.2e-06	0.000138	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—EP300—urinary bladder cancer	5.17e-06	0.000138	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	5.15e-06	0.000137	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MYC—urinary bladder cancer	5.13e-06	0.000137	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	5.1e-06	0.000136	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—TYMS—urinary bladder cancer	5.08e-06	0.000136	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	5.08e-06	0.000136	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—EP300—urinary bladder cancer	5.07e-06	0.000135	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—EP300—urinary bladder cancer	5.07e-06	0.000135	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	5.03e-06	0.000134	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	5.03e-06	0.000134	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	5.02e-06	0.000134	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—SRC—urinary bladder cancer	5.02e-06	0.000134	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—EGFR—urinary bladder cancer	5.02e-06	0.000134	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	4.99e-06	0.000133	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—EP300—urinary bladder cancer	4.98e-06	0.000133	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MYC—urinary bladder cancer	4.96e-06	0.000132	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	4.94e-06	0.000132	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—SRC—urinary bladder cancer	4.93e-06	0.000131	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—KRAS—urinary bladder cancer	4.91e-06	0.000131	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—TP53—urinary bladder cancer	4.9e-06	0.000131	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MYC—urinary bladder cancer	4.88e-06	0.00013	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	4.88e-06	0.00013	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	4.86e-06	0.00013	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—EGFR—urinary bladder cancer	4.85e-06	0.000129	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	4.85e-06	0.000129	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—SRC—urinary bladder cancer	4.84e-06	0.000129	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—TP53—urinary bladder cancer	4.83e-06	0.000129	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GPX1—urinary bladder cancer	4.81e-06	0.000128	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—EGFR—urinary bladder cancer	4.78e-06	0.000127	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—KRAS—urinary bladder cancer	4.74e-06	0.000126	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	4.72e-06	0.000126	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	4.71e-06	0.000126	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—HRAS—urinary bladder cancer	4.68e-06	0.000125	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	4.62e-06	0.000123	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—HRAS—urinary bladder cancer	4.62e-06	0.000123	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—KRAS—urinary bladder cancer	4.58e-06	0.000122	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—KRAS—urinary bladder cancer	4.51e-06	0.00012	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MYC—urinary bladder cancer	4.5e-06	0.00012	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	4.5e-06	0.00012	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	4.44e-06	0.000118	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	4.43e-06	0.000118	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MYC—urinary bladder cancer	4.42e-06	0.000118	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	4.4e-06	0.000117	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—TP53—urinary bladder cancer	4.36e-06	0.000116	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MYC—urinary bladder cancer	4.34e-06	0.000116	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	4.33e-06	0.000116	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	4.33e-06	0.000116	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	4.32e-06	0.000115	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—EGFR—urinary bladder cancer	4.24e-06	0.000113	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—TP53—urinary bladder cancer	4.21e-06	0.000112	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	4.19e-06	0.000112	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—HRAS—urinary bladder cancer	4.17e-06	0.000111	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	4.16e-06	0.000111	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	4.09e-06	0.000109	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	4.08e-06	0.000109	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—TP53—urinary bladder cancer	4.07e-06	0.000109	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	4.03e-06	0.000107	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—HRAS—urinary bladder cancer	4.03e-06	0.000107	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—TP53—urinary bladder cancer	4.01e-06	0.000107	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—KRAS—urinary bladder cancer	4.01e-06	0.000107	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	4.01e-06	0.000107	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	3.94e-06	0.000105	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—HRAS—urinary bladder cancer	3.9e-06	0.000104	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—HRAS—urinary bladder cancer	3.84e-06	0.000102	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PTEN—urinary bladder cancer	3.78e-06	0.000101	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	3.72e-06	9.93e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—TP53—urinary bladder cancer	3.7e-06	9.86e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	3.64e-06	9.7e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—TP53—urinary bladder cancer	3.63e-06	9.68e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—EP300—urinary bladder cancer	3.6e-06	9.61e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PPARG—urinary bladder cancer	3.6e-06	9.6e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—TP53—urinary bladder cancer	3.56e-06	9.5e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	3.54e-06	9.43e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	3.48e-06	9.27e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	3.47e-06	9.25e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3.46e-06	9.22e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—HRAS—urinary bladder cancer	3.41e-06	9.08e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	3.31e-06	8.82e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	3.17e-06	8.44e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.83e-06	7.55e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.47e-06	6.59e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.36e-06	6.28e-05	CbGpPWpGaD
